[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Phianmongkhol Y, Srisomboon J, Nakorn MN: Evaluation of preventing chemotherapy induced oral mucositis project in patients with cancer of the female reproductive system at Maharaj Nakorn Chiang Mai Hospital, Thailand. Asian Pac J Cancer Prev; 2010;11(2):561-6
Genetic Alliance. consumer health - Oral cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of preventing chemotherapy induced oral mucositis project in patients with cancer of the female reproductive system at Maharaj Nakorn Chiang Mai Hospital, Thailand.
  • Oral mucositis is an important and common complication among female patients who have cancer of the reproductive system receiving chemotherapy.
  • This study aimed to evaluate the prevention of chemotherapy-induced oral mucositis project in female reproductive system cancer patients at Maharaj Nakorn Chiang Mai Hospital.
  • Data were collected by using of two forms developed by the researcher; the nurses' opinion form about the project's implementation and a mucositis form.
  • All of them (100.00 %) agreed that the clinical practice guidelines were easily to follow, convenient to use, had good outcome, reduced nursing time, and were satisfied with this project.
  • The results of this study confirm that with the prevention chemotherapy-induced oral mucositis project for female reproductive system cancer patients, care is more efficient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Genital Neoplasms, Female / drug therapy. Nursing Staff, Hospital. Stomatitis / chemically induced. Stomatitis / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Thailand. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843152.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


2. Pagano L, Caira M, Valentini CG, Fianchi L: Clinical aspects and therapy of sporadic burkitt lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical aspects and therapy of sporadic burkitt lymphoma.
  • Burkitt's lymphoma is a highly aggressive mature B-cell neoplasm consisting of endemic, sporadic, and immunodeficiency-associated variants, sharing many morphologic and immunophenotypic features.
  • It is characterized by a high proliferation rate and propensity for extranodal sites such as gastrointestinal tract and reproductive organs.
  • Brief-duration, high-intensity chemotherapy regimens including aggressive central nervous system prophylaxis have had remarkable success in the treatment of this disease in the sporadic form, with very high complete remission rate and overall survival in adults.
  • Although Burkitt's lymphoma is extremely chemosensitive, biologically targeted therapies should be developed, because current treatment options are suboptimal for patients with poor prognostic features or with relapsed disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1130-4 [1515634.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Oligonucleotides. 2005 Summer;15(2):85-93 [15989423.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):941-6 [1709685.001]
  • [Cites] Pediatr Blood Cancer. 2009 Feb;52(2):177-81 [18816698.001]
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Bone Marrow Transplant. 2000 Jun;25(12):1311-3 [10871739.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):889-92 [12153181.001]
  • [Cites] Br J Haematol. 2004 Sep;126(6):815-20 [15352985.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):31-40 [16865529.001]
  • [Cites] Cancer Gene Ther. 2007 Feb;14(2):220-6 [17053816.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2717-24 [18378569.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):240-8 [8558204.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):931-6 [8487057.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(12):1351-4 [11223978.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):615-22 [2313330.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):186-93 [2915234.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):847-58 [3711961.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1695-704 [6697306.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • (PMID = 21416007.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033171
  •  go-up   go-down


3. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JS: Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer; 2000 Jul;83(2):232-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in tumour-bearing nude mice was studied to examine possible applications of pegylated liposome-targeted anti-cancer therapies.
  • Significant reticuloendothelial system uptake was demonstrated with 19.3 +/- 2.8 and 18.8 +/- 4.2% ID g(-1) at 24 h in the liver and spleen, respectively.
  • Other sites of appreciable deposition were the kidney, skin, female reproductive tract and to a lesser extent the gastrointestinal tract.
  • There was no indication of cumulative deposition of pegylated liposomes in the lung, central nervous system, musculoskeletal system, heart or adrenal glands.
  • In contrast, the t1/2alpha and t1/2beta of unencapsulated 111In-DTPA were 5 min and 1.1 h, respectively, with no evidence of accumulation in tumour or normal tissues.
  • The potential applications of pegylated liposomes in the arena of targeted therapy of solid cancers are discussed.
  • [MeSH-minor] Animals. Chelating Agents / pharmacokinetics. Drug Carriers. Drug Delivery Systems. Drug Stability. Female. Humans. Indium Radioisotopes / pharmacokinetics. Mice. Mice, Nude. Neoplasm Transplantation. Time Factors. Tissue Distribution. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 1965 Aug;13(1):238-52 [5859039.001]
  • [Cites] Proc Soc Exp Biol Med. 1955 Jul;89(3):362-4 [13254761.001]
  • [Cites] FEBS Lett. 1987 Oct 19;223(1):42-6 [3666140.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6949-53 [3413128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4 [1763060.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):302-9 [1568796.001]
  • [Cites] Int J Cancer. 1992 Jul 30;51(6):942-8 [1639542.001]
  • [Cites] Semin Oncol. 1992 Aug;19(4 Suppl 11):21-8 [1509278.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5135-43 [1394121.001]
  • [Cites] Am J Pathol. 1993 Jul;143(1):10-4 [8317543.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):959-64 [8335404.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3964-7 [8358724.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3671-5 [8252484.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1478-84 [8111716.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Apr;8(2):431-50 [8040147.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1060-9 [7866989.001]
  • [Cites] Science. 1995 Mar 3;267(5202):1275-6 [7871422.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2169-73 [7697608.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):914-20 [7707119.001]
  • [Cites] Arch Intern Med. 1995 May 22;155(10):1093-8 [7748054.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 18;87(20):1556-7 [7563191.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1074-5 [7577449.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):1029-37 [7490617.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):367-74 [8567337.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):989-94 [8611437.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S271-8 [8763896.001]
  • [Cites] J Infect. 1996 Mar;32(2):133-7 [8708370.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):987-93 [9060537.001]
  • [Cites] Oncology (Williston Park). 1997 Sep;11(9 Suppl 9):63-7 [9330411.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43(1):1-7 [9923534.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):134-7 [9935243.001]
  • [Cites] Lancet. 1974 Jun 29;1(7870):1313-6 [4134296.001]
  • (PMID = 10901376.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Drug Carriers; 0 / Indium Radioisotopes; 0 / Liposomes; 7A314HQM0I / Pentetic Acid
  • [Other-IDs] NLM/ PMC2363473
  •  go-up   go-down


Advertisement
4. Müller J: Impact of cancer therapy on the reproductive axis. Horm Res; 2003;59 Suppl 1:12-20
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cancer therapy on the reproductive axis.
  • Cancer therapy includes surgery, chemotherapy and irradiation.
  • Depending on the diagnosis, the location of the neoplasm and the age of the patient, these treatment modalities may be given alone or in combination.
  • All forms of cancer therapy can affect the hypothalamic-pituitary-gonadal axis.
  • The long-term consequences for reproductive function depend on several aspects.
  • The sensitivity of germ cells to cancer therapy also differs between the sexes.
  • With regard to chemotherapy, the possible damage to the gonads is dependent on the total dose and type of agent given.
  • According to current knowledge, the hypothalamic-pituitary axis is not affected by conventional doses of chemotherapy.
  • Radiotherapy has by far the most damaging effect on the reproductive axis, having serious adverse effects on both the hypothalamic-pituitary area as well as on the gonads themselves.
  • The present review will focus on the late effects of cancer therapy in children and young adults with acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, brain tumour, Hodgkin's lymphoma or Wilms' tumour, including the adverse effects of bone marrow transplantation.
  • [MeSH-major] Hypothalamo-Hypophyseal System / drug effects. Hypothalamo-Hypophyseal System / radiation effects. Neoplasms / complications. Neoplasms / therapy. Ovary / drug effects. Ovary / radiation effects. Testis / drug effects. Testis / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12566715.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gonadal Steroid Hormones
  • [Number-of-references] 70
  •  go-up   go-down


5. Ashraf-Ganjooei T, Ghaemmaghami F: Patients with presenting unusual manifestations with gestational trophoblastic neoplasm: case series and review of literatures. Arch Gynecol Obstet; 2008 May;277(5):465-70
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for trophoblastic neoplasm .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with presenting unusual manifestations with gestational trophoblastic neoplasm: case series and review of literatures.
  • Early recognition of gestational trophoblastic neoplasms (GTN) will maximize the chances of cure with chemotherapy but some patients present with many different symptoms months or even years after the causative pregnancy making diagnosis difficult.
  • Clinicians should be aware of the possibility of GTN in any reproductive age woman with bizarre central nervous system symptoms, gastrointestinal symptoms or radiographic evidence of metastatic tumor of unknown primary origin.
  • [MeSH-major] Brain Neoplasms / diagnosis. Digestive System Neoplasms / diagnosis. Gestational Trophoblastic Disease / diagnosis. Kidney Neoplasms / diagnosis. Splenic Neoplasms / diagnosis


6. Cagayan MS, Lu-Lasala LR: Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital. J Reprod Med; 2006 Oct;51(10):785-92
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital.
  • OBJECTIVE: To evaluate the clinical characteristics, treatment modalities and outcomes of patients with intracranial metastases resulting from gestational trophoblastic neoplasia (GTN).
  • Systemic chemotherapy in the form of methotrexate, etoposide, actinomycin D, cyclophosphamide and vincristine was the treatment of choice.
  • RESULTS: During 1992-2004, 30 patients with stage IV GTN (brain metastases) were diagnosed based on history, physical examination and computed tomography of the brain at the Philippine General Hospital.
  • Of the 30 patients, 17 (56.7%) belonged to the "early" group (having central nervous system [CNS] symptoms on presentation), while 13 (43.3%) were in the "late" group (individuals who developed lesions during chemotherapy or who had relapsed after initial complete or partial remission).
  • Thirteen received etoposide, methotrexate, actinomycin D with cisplatin and etoposide, 5 received EMACE, 6 received methotrexate actinomycin-D and cyclophosphamide and 1 received methotrexate, etoposide, actinomycin-D.
  • Eight (27%) patients responded to treatment and were considered in remission; remission was achieved in 6 of 17 (35%) in the early group and 2 of 13 (15%) in the late group.
  • The mean survival time for the early CNS group was 7.3 months; it was 8.3 months for the late CNS group.
  • CONCLUSION: Intracranial metastasis in GTN is a curable disease that carries compromised survival because of difficulty in implementing the treatment regimen, patient noncompliance and late diagnosis.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Gestational Trophoblastic Disease / epidemiology. Uterine Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Injections, Spinal. Medical Records. Methotrexate / administration & dosage. Middle Aged. Neoplasm Metastasis. Philippines / epidemiology. Pregnancy. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17086807.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; EMA-CO protocol
  •  go-up   go-down


7. Kim SJ, Na YJ, Jung SG, Kim CJ, Bae SN, Lee C: Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience. J Reprod Med; 2007 Sep;52(9):819-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To test the efficacy of a new scoring system to differentiate high-risk hydatidiform mole (H-mole) and initiate early selective postmolar chemotherapy.
  • STUDY DESIGN: According to Kim's scoring system, 262 patients were identified as high-risk H-mole patients.
  • Fifty (19.1%) received early chemotherapy, and the rest constituted the control group.
  • Salvage therapy with etoposide, methotrexate, actinomycin D/etoposide, cisplatin (EMA/EP) and taxol, cisplatin/taxol, etoposide (TP/TE) was applied in 21 cases of ultra-high-risk GTT.
  • RESULTS: None of the 50 cases in the early chemotherapy group progressed to persistent GTT.
  • However, 58.9% in the control group developed GTT with 8.0% drug resistance.
  • Of those receiving salvage therapy in the 21 ultra-high-risk GTT cases resistant to EMA/CO, 10 of 14 (71%) receiving EMA/EP and 4 of 7 (57.1%) receiving TP/TE achieved remission.
  • CONCLUSION: Early postmolar chemotherapy for high-risk H-mole is effective in preventing progression to persistent GTT and treatment failure.
  • Ultra-high-risk GTT should be approached with multimodal treatment, including EMA/EP and TP/TE regimens.
  • [MeSH-major] Hydatidiform Mole / drug therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cisplatin / administration & dosage. Dactinomycin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Korea. Methotrexate / administration & dosage. Middle Aged. Paclitaxel / administration & dosage. Pregnancy. Prospective Studies. Registries. Retrospective Studies. Risk Factors. Salvage Therapy. Severity of Illness Index

  • Genetic Alliance. consumer health - Hydatidiform mole.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939600.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Okines AF, Morris R, Hancock BW: An evaluation of FIGO 2000: the first 5 years. J Reprod Med; 2008 Aug;53(8):615-22
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the International Federation of Gynecology and Obstetrics 2000 Gestational Trophoblastic Neoplasia (GTN) staging and classification system and to identify any factors predictive of failure of first-line chemotherapy.
  • Data were collected on all patients who received treatment for GTN at the center (n = 132).
  • Of those, 38 of 107 (35.5%) of patients who scored as low risk and 2 of 15 (13.3%) of patients who scored as high risk required salvage chemotherapy.
  • No statistically significant predictive factors for treatment failure were identified.
  • There was a trend toward association with increased age at diagnosis: 48.8% of patients aged > or = 30 required second-line therapy compared to 33.3% aged < 30 (p = 0.098).
  • CONCLUSION: Approximately one third of women treated on the low-risk regimen will require salvage chemotherapy, but this does not affect their survival.
  • Women aged > or = 30 may be at particular risk of treatment failure so could be offered high-risk chemotherapy from the outset.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gestational Trophoblastic Disease / drug therapy. Gestational Trophoblastic Disease / pathology. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773627.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Lurain JR: Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med; 2002 Jun;47(6):451-9
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multimodality therapy with combination chemotherapy employing etoposide, high-dose methotrexate, actinomycin D, cyclophosphamide and vincristine and adjuvant radiotherapy and surgery, when indicated, has resulted in cure rates of 80-90% in patients with high-risk metastatic gestational trophoblastic tumors.
  • However, 25-30% of high-risk patients will have an incomplete response to first-line chemotherapy or will relapse from remission.
  • Most of these patients will have a clinicopathologic diagnosis of choriocarcinoma, multiple metastases to sites other than the lung and vagina, and failed or inappropriate previous chemotherapy, resulting in very high World Health Organization scores.
  • Salvage chemotherapy with cisplatin/etoposide, usually in conjunction with bleomycin or ifosfamide, as well as surgical resection of sites of resistant disease in selected patients, will result in a cure for most patients.
  • Colony-stimulating factors should be used to prevent treatment delays and dose reductions.
  • Newer anticancer agents, such as paclitaxel and gemcitibine, and high-dose chemotherapy with or without autologous bone marrow transplantation or peripheral blood stem cell support may play a role in the future management of selected patients.
  • [MeSH-major] Gestational Trophoblastic Disease / therapy. Pregnancy, High-Risk
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Central Nervous System Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Hysterectomy. Liver Neoplasms / secondary. Neoplasm Staging / methods. Neoplasm Staging / standards. Patient Selection. Pregnancy. Pregnancy Outcome. Radiotherapy, Adjuvant. Remission Induction. Risk Factors. Salvage Therapy / methods. Stem Cell Transplantation. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12092013.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


10. Ozalp SS: Regional perspectives on gestational trophoblastic disease in Turkey. J Reprod Med; 2008 Aug;53(8):639-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to this study, a clinical classification system was used for gestational trophoblastic neoplasia by 60% of the hospitals.
  • Methotrexate was the single-agent chemotherapy used most frequently.
  • With regard to first-line combined chemotherapy, MAC (methotrexate, actinomycin, chlorambucil) was the preferred combination.
  • From more recent studies, EMA-CO is the first-line combination chemotherapy.
  • There is no national registry system for GTD in Turkey.
  • There appears to be a need to conduct properly designed community-based studies with well-established case registry system in Turkey.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diet. Female. Humans. Incidence. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Rural Population. Socioeconomic Factors. Turkey / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Gestational Trophoblastic Disease.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773631.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Qamar L, Davis R, Anwar A, Behbakht K: Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Gynecol Oncol; 2008 Sep;110(3):425-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Novel strategies for the treatment of chemoresistant ovarian cancer are needed.
  • Caffeine and related compounds have been shown to over-ride G2/M arrest in ovarian cancer cells, increasing toxicity to chemotherapy.
  • Newer compounds have been developed which may have the same effect as and exhibit synergism with caffeine, allowing the use of lower doses.
  • CONCLUSIONS: Gö6976, when added to caffeine at doses below that required for cell-cycle over-ride, augments caffeine in overcoming CDDP resistance in this experimental system.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Caffeine / pharmacology. Carbazoles / pharmacology. Cisplatin / pharmacology. Ovarian Neoplasms / drug therapy. Protein Kinase C / antagonists & inhibitors
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Division / drug effects. Cell Growth Processes / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Synergism. Female. G2 Phase / drug effects. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619662.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / NCI-K12 86913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbazoles; 136194-77-9 / Go 6976; 3G6A5W338E / Caffeine; EC 2.7.11.13 / Protein Kinase C; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Irvin WP, Rice LW, Berkowitz RS: Advances in the management of endometrial adenocarcinoma. A review. J Reprod Med; 2002 Mar;47(3):173-89; discussion 189-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial adenocarcinoma is the most common and curable gynecologic neoplasm; the five-year survival for women with surgical stage I disease ranges from 83% to 93%; stage II, 73%; stage III, 52%; and stage IV, 27%.
  • The absence of an asymptomatic latency phase amenable to detection through screening and the already excellent cure rates seen with early-stage disease have precluded the need for endometrial cancer screening programs.
  • Recent studies suggest a therapeutic benefit associated with extensive retroperitoneal lymph node evaluation to determine the disease extent and thereby more effectively direct potentially life-saving adjuvant therapy.
  • Adjuvant radiation therapy, known to have survival benefit in advanced-stage disease, may also have survival benefit in intermediate-risk surgical stage I disease on the basis of results recently released from a Gynecologic Oncology Group study.
  • The use of radiation therapy, systemic chemotherapy and hormonal therapy, alone or in combination, is recommended for primary advanced and recurrent disease.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Neoplasm Staging
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Incidence. Radiotherapy, Adjuvant. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11933681.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


13. DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH: Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecol Oncol; 2008 Feb;108(2):355-60
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Current firstline chemotherapy for ovarian cancer consists of carboplatin combined with either paclitaxel or docetaxel.
  • Specifically, the PK of DOC was correlated with the ratio of CYP4A5 to ABCB1 gene expression, thus representing a novel mechanism of chemotherapy resistance.
  • CONCLUSIONS: Knowledge of inter-individual variation in CYP450 enzyme and ABC transporter tumor expression and activity may influence the individualization of chemotherapy, by avoiding agents that are rapidly metabolized and selecting agents that are not.
  • [MeSH-major] Cytochrome P-450 Enzyme System / metabolism. Ovarian Neoplasms / enzymology. P-Glycoprotein / metabolism. Paclitaxel / pharmacokinetics. Taxoids / pharmacokinetics
  • [MeSH-minor] Antineoplastic Agents / pharmacokinetics. Aryl Hydrocarbon Hydroxylases / biosynthesis. Aryl Hydrocarbon Hydroxylases / genetics. Aryl Hydrocarbon Hydroxylases / metabolism. Cytochrome P-450 CYP2C8. Cytochrome P-450 CYP3A. Female. Gene Expression. Humans. Neoplasm Staging. P-Glycoproteins. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063021.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Taxoids; 15H5577CQD / docetaxel; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2C8 protein, human; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2C8; EC 1.14.14.1 / Cytochrome P-450 CYP3A; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Sasaki S: The Japanese trophoblastic disease classification. J Reprod Med; 2004 Aug;49(8):637-42
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinical usefulness of the "diagnostic score"for the detection of choriocarcinoma in persistent gestational trophoblastic disease without histologic findings.
  • STUDY DESIGN: We reviewed the clinical records of and histologic reports on all 809 patients with persistent gestational trophoblastic disease treated with surgery and chemotherapy in Japan.
  • CONCLUSION: The diagnostic score is a unique scoring system for differentiating choriocarcinoma clinically from persistent gestational trophoblastic disease without histologic findings and for selecting the most appropriate chemotherapy.
  • The scoring system should be very useful for comparing the nearly true incidence and treatment results with choriocarcinoma between nations.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Japan. Neoplasm Invasiveness. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15457854.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Wicherek L, Galazka K, Lazar A: RCAS1 decidual immunoreactivity during placental abruption: immune cell presence and activity. Am J Reprod Immunol; 2007 Jul;58(1):46-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RCAS1 decidual immunoreactivity during placental abruption: immune cell presence and activity.
  • The present study evaluates the immunoreactivity level of RCAS1 with respect to immune cell status during placental abruption (PA) and retained placental tissue (RPT).
  • METHOD OF STUDY: RCAS1, CD3, CD56, CD69 and CD25 immunoreactivity was assessed by immunohistochemistry in 66 decidual samples derived from PA and from RPT.
  • RESULTS: RCAS1 immunoreactivity was statistically significantly higher in decidual tissue samples derived from patients with RPT than in those derived from patients with PA.
  • CONCLUSION: Placental abruption seems to be associated with excessive accumulation and activity of CD3(+) and CD56(+) cells in decidua, which processes might, in turn, result from an insufficient RCAS1 decidual level.
  • [MeSH-major] Abruptio Placentae / metabolism. Antigens, Neoplasm / metabolism. Decidua / immunology. Immune System / metabolism

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565547.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human
  •  go-up   go-down


16. Hasegawa A, Fu Y, Koyama K: Nasal immunization with diphtheria toxoid conjugated-CD52 core peptide induced specific antibody production in genital tract of female mice. Am J Reprod Immunol; 2002 Nov;48(5):305-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROBLEM: The common mucosal immune system (CMIS) has developed as a barrier for the numerous encounters between the host and various pathogens.
  • It is possible to exploit this system to induce secretion of IgA antibody which inhibits sperm penetration in the female genital tract.
  • METHOD OF STUDY: A synthetic peptide corresponding to CD52 core peptide (GQNDTSQTSSPS) was prepared and conjugated with diphtheria toxoid (DT) as a carrier protein.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Neoplasm / immunology. Diphtheria Toxoid / immunology. Glycoproteins / immunology. Immunotoxins / immunology. Vaccination. Vagina / immunology

  • MedlinePlus Health Information. consumer health - Immunization.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12516652.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Diphtheria Toxoid; 0 / Glycoproteins; 0 / Immunoglobulin A; 0 / Immunotoxins; 0 / Liposomes; 0 / Peptides
  •  go-up   go-down


17. Savage P, Seckl M, Short D: Practical issues in the management of low-risk gestational trophoblast tumors. J Reprod Med; 2008 Oct;53(10):774-80
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using data primarily from Charing Cross Hospital in London, we examined the organization and funding of patients' care and follow-up, the value of second evacuations, the indications for treatment escalation and the results of treating patients with persistent low levels of human chorionic gonadotropin (hCG) following a molar pregnancy.
  • In the U.K. system the total cost per patient treated is approximately $30,000.
  • Outcome analysis of patients with low-risk gestational trophoblastic tumor (GTT) treated with methotrexate/folinic acid indicates that hCG levels in excess of500 IU/L at 7 weeks after starting are an accurate predictor of impending methotrexate resistance.
  • For patients with hCG values under 100 IU/L at the time of treatment, a review of the 30 most recent low-risk GTT patients demonstrates a 100% cure rate with standard treatment.
  • National or regional organization of follow-up and treatment is simple, economic and associated with enhanced outcomes when appropriate treatment policies are followed.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin / blood. Gestational Trophoblastic Disease / drug therapy. Hydatidiform Mole / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Resistance, Neoplasm. Female. Humans. Leucovorin / therapeutic use. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / epidemiology. Pregnancy. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004403.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Chorionic Gonadotropin; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 38
  •  go-up   go-down


18. Bolla M, Berland E, Salvat J, Artignan X, de Cornulier J, Colonna M: Fast growing cervical carcinomas. A retrospective analysis of 20 IB-IIB FIGO. Eur J Obstet Gynecol Reprod Biol; 2000 May;90(1):81-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Twenty cases of fast-growing cancer of the uterine cervix classified according to the FIGO clinical staging system as IB (n=14), IIA (3), and IIB (3), have been reviewed and compared to a cohort of 160 cases not having this feature.
  • The treatment policy was equally distributed between a radio-surgical approach, cesium 137 intracavitary irradiation followed by radical hysterectomy and lymphadenectomy, or a definitive irradiation with pelvic external irradiation followed by cesium 137 intracavitary irradiation.
  • CONCLUSION: These poor results emphasize the need to intensify loco-regional therapy with a concurrent cisplatin-based chemotherapy within the framework of a multidisciplinary approach.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Rate. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10767516.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  •  go-up   go-down


19. Papadopoulos AJ, Foskett M, Seckl MJ, McNeish I, Paradinas FJ, Rees H, Newlands ES: Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med; 2002 Jun;47(6):460-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe 34 cases of placental site trophoblastic tumor (PSTT) treated at Charing Cross Hospital over 25 years.
  • Excluding the seven deaths, the primary treatment was surgery alone in 10 cases (37%) (8 hysterectomies and 2 dilatation and curettages); 4 had surgery followed by adjuvant chemotherapy; 5 had neoadjuvant chemotherapy followed by surgery; 1 had chemotherapy alone, and the disease recurred and was successfully rechallenged; and 5 had surgery between chemotherapy cycles.
  • The WHO scoring system for GTD did not correlate with this outcome.
  • Patients with PSTT should be managed separately from those with other types of GTD, as the disease behavior is different.
  • [MeSH-major] Trophoblastic Tumor, Placental Site / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Birth Intervals. Cause of Death. Chemotherapy, Adjuvant. Chorionic Gonadotropin / blood. Combined Modality Therapy. Female. Humans. Hysterectomy. London / epidemiology. Maternal Age. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome. Uterine Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12092014.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin
  •  go-up   go-down


20. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol; 2003 Aug;90(2):390-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.
  • METHODS: Patients (408) with stage IIIC epithelial ovarian cancer had cytoreductive surgery before systemic platinum-based combination chemotherapy.
  • A ranking system (0-3) was devised to prospectively quantify the extent of disease involving:.
  • (1) right upper quadrant (diaphragm/hepatic, and adjacent peritoneal surfaces), (2) left upper quadrant (omentum/gastro-colic ligament, spleen, stomach, transverse colon, splenic flexure of colon), (3) pelvis (reproductive organs, recto-sigmoid, pelvic peritoneum), (4) retroperitoneum (pelvic/aortic nodes), and (5) central abdomen (small bowel, ascending/descending colon, mesentery, anterior abdominal wall, pericolic gutters).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12893206.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Cicchillitti L, Della Corte A, Di Michele M, Donati MB, Rotilio D, Scambia G: Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin. Int J Oncol; 2010 Aug;37(2):445-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian cancer is the second most frequently diagnosed malignancy of the reproductive system and is the leading cause of gynecological cancer mortality.
  • Although the majority of advanced ovarian carcinomas initially respond successfully to taxane-based chemotherapy, resistance to chemotherapy remains the primary factor accounting for the low 5-year survival in this patient population.
  • [MeSH-major] Actins / chemistry. Drug Resistance, Neoplasm. Multiprotein Complexes / analysis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Paclitaxel / pharmacology. Protein Disulfide-Isomerases / metabolism
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Chromosome Segregation / drug effects. Chromosome Segregation / physiology. Female. Humans. Protein Binding. Protein Conformation. Protein Multimerization / physiology. Structure-Activity Relationship

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596672.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Antineoplastic Agents, Phytogenic; 0 / Multiprotein Complexes; EC 5.3.4.1 / Protein Disulfide-Isomerases; EC 5.3.4.1. / PDIA3 protein, human; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Rivera JA, Christopoulos S, Small D, Trifiro M: Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J Clin Endocrinol Metab; 2004 Jul;89(7):3183-8
Hazardous Substances Data Bank. RALOXIFENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign metastasizing leiomyomas (BMLs) occur predominantly in women during reproductive years.
  • The most commonly affected organs are the lungs, but BMLs have been reported in lymph nodes, deep soft tissues, mesentery, bones, the central nervous system, and the heart.
  • Radical interventions, such as extensive tumor debulking and oophorectomy for hormonal control, although effective in many cases, are not always possible or desirable and carry significant morbidity.
  • Here we present two cases of BMLs to illustrate the role of newer therapeutic agents, the estrogen receptor modulators and the aromatase inhibitors, in the hormonal manipulation of these tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Brachial Plexus Neuropathies / drug therapy. Enzyme Inhibitors / therapeutic use. Leiomyoma / drug therapy. Leiomyoma / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aromatase Inhibitors. Estrogen Receptor Modulators / therapeutic use. Female. Gonadotropin-Releasing Hormone / agonists. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Neoplasms / diagnosis. Neoplasms / drug therapy. Nitriles / therapeutic use. Radiography, Thoracic. Raloxifene Hydrochloride / therapeutic use. Selective Estrogen Receptor Modulators / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15240591.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Estrogen Receptor Modulators; 0 / Nitriles; 0 / Selective Estrogen Receptor Modulators; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; 33515-09-2 / Gonadotropin-Releasing Hormone; 4F86W47BR6 / Raloxifene Hydrochloride
  • [Number-of-references] 53
  •  go-up   go-down






Advertisement